<DOC>
	<DOCNO>NCT02636036</DOCNO>
	<brief_summary>This Phase I multicenter , open label , nonrandomized study enadenotucirev administer combination nivolumab subject metastatic advanced epithelial tumor ( focus CRC , UCC , SCCHN salivary gland cancer ) respond standard therapy .</brief_summary>
	<brief_title>Phase I Study Enadenotucirev PD-1 Inhibitor Subjects With Metastatic Advanced Epithelial Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Adult male female age 18 year Diagnosis metastatic advance CRC , UCC , SCCHN , salivary gland cancer NSCLC tumor accessible biopsy Dose expansion : Subjects must least one measurable site disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ; lesion must outside previously irradiated area Disease status : Dose escalation phase : Subject respond standard therapy standard treatment exist Dose expansion phase : Subject respond standard therapy standard treatment exist : CRC No four different prior line systemic therapy advance disease UCC SCCHN salivary gland cancer No three different prior treatment regimen advanced/metastatic set maximum two chemotherapycontaining regimen NSCLC Prior treatment regimen must include platinumbased therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Predicted life expectancy 3 month Ability comply study procedure Investigator 's opinion Recovered Grade 1 effect ( exclude alopecia ) prior therapy malignancy Adequate renal function : Creatinine ≤1.5 mg/dL calculate creatinine clearance use CockcroftGault formula ≥60 mL/min measure creatinine clearance Proteinuria : dipstick ≤2+ Adequate hepatic function : Serum bilirubin &lt; 1.5 mg/dL ( except subject Gilbert 's syndrome may total bilirubin &lt; 3.0 mg/mL ) Aspartate aminotransferase alanine aminotransferase ≤3 x upper limit normal ( ULN ) Albumin ≥3 g/dL Lipase : 1.5 x ULN . Subjects lipase &gt; 1.5 x ULN may enrol neither clinical radiographic sign pancreatitis Amylase : 1.5 x ULN . Subjects amylase &gt; 1.5 x ULN may enrol neither clinical radiographic sign pancreatitis Adequate bone marrow function : Absolute neutrophil count ≥1.5 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥90 g/L Adequate coagulation test : international normalized ratio ≤1.5 Normal thyroid pituitary function For female childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) , negative serum pregnancy test must document 14 day first dose study treatment For female postmenopausal ( 24 month amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement use two adequate method contraception , study treatment period least 6 month last dose study treatment For male : agreement use barrier method contraception study treatment period least 6 month last dose study treatment Subjects must provide write informed consent participate Willing consent tumor biopsy study Pregnant breastfeeding female Known history evidence significant immunodeficiency due underlie illness ( e.g . human immunodeficiency virus [ HIV ] /acquired immunodeficiency syndrome [ AIDS ] ) and/or medication ( e.g . systemic corticosteroid immunosuppressive medication , include cyclosporine , azathioprine , interferon 4 week first dose study treatment ) . Subjects condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisolone equivalent ) immunosuppressive medication within 14 day first dose study treatment . Inhaled topical steroid adrenal replacement steroid dos permit absence autoimmune disease Splenectomy Prior allogeneic autologous bone marrow organ transplantation Subjects active , know suspected autoimmune disease syndrome require systemic immunosuppressive agent ; subject vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune disease require hormone replacement , psoriasis require systemic treatment condition expect recur absence external trigger permit enrol History idiopathic pulmonary fibrosis , drug induce pneumonitis , evidence active pneumonia pneumonitis compute tomography scan Active infection require antibiotic , physician monitoring recurrent fever &gt; 100.4˚F ( 38.0˚C ) associate clinical diagnosis active infection Active viral disease positive test hepatitis B virus use hepatitis B surface antigen test positive test hepatitis C virus ( HCV ) use HCV ribonucleic acid HCV antibody test indicate acute chronic infection . Positive test HIV AIDS ; test require absence history Use follow antiviral agent : ribavirin , adefovir , lamivudine cidofovir within 7 day prior first dose study treatment ; pegylated interferon 14 day first dose study treatment Prior treatment PD1 program death ligand ( PDL ) 1 inhibitor Administration investigational drug 28 day first dose study treatment Major surgery treatment chemotherapy , radiation therapy , biologics cancer investigational therapy 28 day first dose study treatment ( subject prior cytotoxic investigational product &lt; 3 week prior study treatment might eligible discussion Investigator Medical Monitor , toxicities prior treatment resolve NCI CTCAE Grade 1 ) . All toxicity attribute prior anticancer therapy alopecia fatigue must resolve Grade 1 baseline first dose study treatment . Subjects toxicity attribute prior anticancer therapy expect resolve result long lasting sequela , neuropathy platinum base therapy , permit enrol Other prior malignancy active within previous 3 year except local organ confine early stage cancer definitively treat curative intent , require ongoing treatment , evidence residual disease negligible risk recurrence therefore unlikely interfere primary secondary endpoint study , include response rate safety Symptomatic brain metastasis leptomeningeal metastasis symptomatic and/or require treatment . Subjects brain metastasis eligible locally treat ( surgery , radiotherapy ) . There must also requirement immunosuppressive dos systemic corticosteroid ( &gt; 10 mg/day prednisone equivalent ) least 2 week first dose study treatment Any serious uncontrolled medical disorder , opinion Investigator Medical Monitor , may increase risk associate study participation study treatment administration , impair ability subject receive protocol therapy interfere interpretation study result Known allergy enadenotucirev , nivolumab excipients Any medical psychological condition would preclude participation study compromise ability give inform consent Dependence continuous supplemental oxygen use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>